Background: Parkinson’s disease (PD) is one of many neurodegenerative diseases with symptomatic management, and with the correct pattern of pharmacological treatment PD may have an improved quality of life for a minimum of three years. This study aimed to illustrate treatment patterns and comorbidities in PD patients at Dr. Hasan Sadikin General Hospital, Bandung.Methods: This study was a cross-sectional descriptive study by using total medical records of the period of 2013 to 2018. PD patients receiving pharmacological treatments such as levodopa, anticholinergics, dopamine agonists, or combined therapy were included. Patients with incomplete data and with the previous history of other neurological diseases before PD were excluded from thi...
Parkinson’s disease is the second most frequent neurodegenerative disorder. There is significantly e...
Parkinson’s disease (PD) is a chronic neurodegenerative disease associated with substantial morbid...
Since the discovery of levodopa (L-dopa) in 1967, the range of medications available to treat Parkin...
Background: Parkinson’s disease (PD) is one of many neurodegenerative diseases with symptomatic mana...
Introduction: Parkinson`s disease (PD) is the second most common neurodegenerative condition affecti...
Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alz...
Background: Parkinson's disease (PD) is a neurodegenerative disorder, with male preponderance. It is...
Background: Parkinson's disease (PD) is a highly debilitating disease characterized by tremors, brad...
Background: Parkinson’s disease (PD) is a progressive neurological that disorder is characterized by...
Objectives: To investigate the effectiveness of integrative therapy on prevalence and length of hosp...
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disease following Alzheimer’s disea...
Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzh...
Introduction: Parkinson’s Disease (PD) is the second most frequent neurodegenerative disease and dop...
Objective. The aim of this study is to compare Parkinson’s disease (PD) treatment practices by movem...
Parkinson’s disease (PD) is a progressive and disabling neurological disorder that affects approxima...
Parkinson’s disease is the second most frequent neurodegenerative disorder. There is significantly e...
Parkinson’s disease (PD) is a chronic neurodegenerative disease associated with substantial morbid...
Since the discovery of levodopa (L-dopa) in 1967, the range of medications available to treat Parkin...
Background: Parkinson’s disease (PD) is one of many neurodegenerative diseases with symptomatic mana...
Introduction: Parkinson`s disease (PD) is the second most common neurodegenerative condition affecti...
Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alz...
Background: Parkinson's disease (PD) is a neurodegenerative disorder, with male preponderance. It is...
Background: Parkinson's disease (PD) is a highly debilitating disease characterized by tremors, brad...
Background: Parkinson’s disease (PD) is a progressive neurological that disorder is characterized by...
Objectives: To investigate the effectiveness of integrative therapy on prevalence and length of hosp...
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disease following Alzheimer’s disea...
Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzh...
Introduction: Parkinson’s Disease (PD) is the second most frequent neurodegenerative disease and dop...
Objective. The aim of this study is to compare Parkinson’s disease (PD) treatment practices by movem...
Parkinson’s disease (PD) is a progressive and disabling neurological disorder that affects approxima...
Parkinson’s disease is the second most frequent neurodegenerative disorder. There is significantly e...
Parkinson’s disease (PD) is a chronic neurodegenerative disease associated with substantial morbid...
Since the discovery of levodopa (L-dopa) in 1967, the range of medications available to treat Parkin...